Institute of Cancer Research, United Kingdom: Breast Neoplasms trials

The registry lists 23 Breast Neoplasms studies with Institute of Cancer Research, United Kingdom as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 8Phase 3 6No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
• Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsCompletedNCT00253422Phase 3Results posted
• Digital Delivery of Information About Genetic Testing for Breast CancerCompletedNCT04842799Not applicable
• Exploring the Link Between Cancer Genetics and PPSPStatus unknownNCT04007861
• KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast CancerActive, not recruitingNCT03946202Phase 2
• The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
• A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer PatientsStatus unknownNCT03145961Phase 2
• KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour ResponseCompletedNCT02757651Phase 1/2
• Assessing Treatment Response in Breast Cancer With Functional ImagingCompletedNCT02688257
• Evolution of Resistance to Systemic Therapies in Patients With Breast CancerTerminatedNCT02257775
• MR Characterisation/Localisation of Breast CancerCompletedNCT01567137
• Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast CancerActive, not recruitingNCT01104571Phase 3
• Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast CancerStatus unknownNCT00818051Phase 3
• Radiation Therapy in Women With Low Risk Early-Stage Breast Cancer Who Have Undergone Breast Conservation SurgeryStatus unknownNCT00814567Not applicable
• Triple Negative Breast Cancer TrialStatus unknownNCT00532727Phase 3
• Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryStatus unknownNCT00301925Phase 3
• Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast CancerCompletedNCT00299286Phase 2
• Radiation Therapy in Treating Women With Localized Breast CancerCompletedNCT00107497Not applicable
• Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast CancerStatus unknownNCT00079248Not applicable
• Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for CancerStatus unknownNCT00077090Phase 2
• Combination Chemotherapy in Treating Women With Resected Breast CancerStatus unknownNCT00033683Phase 2
• Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast CancerCompletedNCT00031850Not applicable
• Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerCompletedNCT00002582Phase 3